By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



100 Cumming Center, Suite 151-B
Suite A225
Beverly  Massachusetts  01915  U.S.A.
Phone: 978-236-8717 Fax: 978-921-6564


Company News
Cellceutix (CTIX) Announces Positive Top-Line Data From Phase 2b ABSSSI Trial; Single-Dose Brilacidin Comparable To 7-Days Of Daptomycin 10/23/2014 10:47:29 AM
Cellceutix (CTIX) Investigational New Drug (IND) Application Becomes Effective, Selects First Site For Phase 2 Clinical Trial Of New Treatment For Oral Mucositis 10/13/2014 10:55:18 AM
Cellceutix (CTIX) Provides Update To Shareholders 9/26/2014 2:45:17 PM
Cellceutix (CTIX) To President Obama: We Have The Tools And Will Rise Up To The Challenge To Prevent Antibiotic Resistant Bacteria Becoming A Serious Threat To Public Health 9/22/2014 1:39:29 PM
Cellceutix (CTIX) Provides Initial Observations Of Completed ABSSSI Phase 2b Trial; Company Submits Investigational New Drug Application To FDA For Phase 2 Trial Of Brilacidin-OM For Oral Mucositis 9/10/2014 11:31:01 AM
Cellceutix (CTIX) To Present At Rodman & Renshaw's 16th Annual Global Investment Conference 9/8/2014 12:37:20 PM
Cellceutix (CTIX) Appoints Dr. Barry Schechter To Board Of Directors As Company Focuses On Meeting Requirements For Stock Exchange Uplisting 9/2/2014 2:05:32 PM
Cellceutix (CTIX) Completes Enrollment In Phase 2b Clinical Trial Of Brilacidin For Acute Bacterial Skin And Skin Structure Infections (ABSSSI) 8/19/2014 11:31:24 AM
Cellceutix (CTIX) Anti-Psoriasis Drug Prurisol Meets Primary Endpoint Of Clinical Trial 8/7/2014 10:16:59 AM
Cellceutix (CTIX) Believes Brilacidin On Track To Help U.S. Avoid Falling Into Post-Antibiotic Era; Completion of Enrollment In Phase 2b Trial For Acute Bacterial Skin And Skin Structure Infections Expected This Month 8/4/2014 11:31:29 AM